## **Product** Data Sheet



Cat. No.: HY-141274 CAS No.: 58884-35-8 Molecular Formula:  $C_9H_8N_4O$ Molecular Weight: 188.19

Target: **PROTAC Linkers** 

Pathway: **PROTAC** 

Storage: Powder -20°C 3 years

2 years

In solvent -80°C 6 months

> -20°C 1 month

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (531.38 mM; Need ultrasonic)

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	5.3138 mL	26.5689 mL	53.1378 mL
ototi ostations	5 mM	1.0628 mL 5.3138 mL 10.6276 mL	10.6276 mL	
	10 mM	0.5314 mL	2.6569 mL	5.3138 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (13.28 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility: ≥ 2.5 mg/mL (13.28 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	4-(6-Methyl-1,2,4,5-tetrazin-3-yl)phenol is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs [1].
IC <sub>50</sub> & Target	Alkyl-Chain
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES	
1]. An S, et al. Small-molecule	e PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
	Caution: Product has not been fully validated for medical applications. For research use only.
	Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
	Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com